Research programme: cancer therapeutics - Oxis Biotech

Drug Profile

Research programme: cancer therapeutics - Oxis Biotech

Alternative Names: OXS 1950; OXS 2050; OXS 2175; OXS 4550

Latest Information Update: 12 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxis Biotech
  • Class Bispecific antibodies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Cell adhesion molecule inhibitors; Cell adhesion molecule modulators; Frizzled 7 receptor antagonists; Frizzled 7 receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Cancer

Most Recent Events

  • 12 Apr 2015 Preclinical trials in Breast cancer in USA (unspecified route)
  • 01 Apr 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top